Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 May;17(3):283-293.
doi: 10.1007/s11523-022-00888-9. Epub 2022 Jun 17.

Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study

Tanya Trippett  1 , Helen Toledano  2 , Quentin Campbell Hewson  3 , Arnauld Verschuur  4 , Anne-Marie Langevin  5 , Isabelle Aerts  6 , Lisa Howell  7 , Soledad Gallego  8 , Claudia Rossig  9 , Amy Smith  10 , Darshak Patel  11   12 , Leonardo R Pereira  13 , Sravanthi Cheeti  14 , Luna Musib  14   15 , Katherine E Hutchinson  16 , Clare Devlin  17 , Ronald Bernardi  18 , Birgit Geoerger  19
Affiliations
Clinical Trial

Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study

Tanya Trippett et al. Target Oncol. 2022 May.

Abstract

Background: The MAPK pathway is an emerging target across a number of adult and pediatric tumors. Targeting the downstream effector of MAPK, MEK1, is a proposed strategy to control the growth of MAPK-dependent tumors.

Objective: iMATRIX-cobi assessed the safety, pharmacokinetics, and anti-tumor activity of cobimetinib, a highly selective MEK inhibitor, in children and young adults with relapsed/refractory solid tumors.

Patients and methods: This multicenter Phase I/II study enrolled patients aged 6 months to < 30 years with solid tumors with known/expected MAPK pathway involvement. Patients received cobimetinib tablet or suspension formulation on Days 1-21 of a 28-day cycle. Dose escalation followed a rolling 6 design. The primary endpoint was safety; secondary endpoints were pharmacokinetics and anti-tumor activity.

Results: Of 56 enrolled patients (median age 9 years [range 3-29]), 18 received cobimetinib tablets and 38 cobimetinib suspension. Most common diagnoses were low-grade glioma (LGG; n = 32, including n = 12 in the expansion cohort) and plexiform neurofibroma within neurofibromatosis type 1 (n = 12). Six patients (11 %) experienced dose-limiting toxicities (including five ocular toxicity events), which established a pediatric recommended Phase II dose (RP2D) of 0.8 mg/kg tablet and 1.0 mg/kg suspension. Most frequently reported treatment-related adverse events were gastrointestinal and skin disorders. Steady state mean exposure (Cmax, AUC0-24) of cobimetinib at the RP2D (1.0 mg/kg suspension) was ~ 50 % lower than in adults receiving the approved 60 mg/day dose. Overall response rate was 5.4 % (3/56; all partial responses in patients with LGG).

Conclusions: The safety profile of cobimetinib in pediatrics was similar to that reported in adults. Clinical activity was observed in LGG patients with known/suspected MAPK pathway activation. Cobimetinib combination regimens may be required to improve response rates in this pediatric population.

Clinical trial registration: ClinicalTrials.gov NCT02639546, registered December 24, 2015.

PubMed Disclaimer

Conflict of interest statement

TT reports consultancy fees from F. Hoffmann-La Roche Ltd. HT reports lecture fees from AstraZeneca and Roche. SG reports personal fees from Bayer, EUSA Pharma, and LOXO Oncology. CR reports personal fees from Amgen, BMS, Celgene, Genentech, Inc., Novartis, Pfizer, and F. Hoffmann-La Roche Ltd. DP was an employee of F. Hoffman-La Roche Ltd. at the time of study conduct. LM was an employee of Genentech, Inc. at the time of study conduct. LRP is an employee of F. Hoffmann-La Roche Ltd. SC, KEH, CD, and RB are employees of and stock-holders in F. Hoffmann-La Roche Ltd/Genentech, Inc. All other authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Patient status
Fig. 2
Fig. 2
Mean (±SD) plasma concentration-time profiles for cobimetinib following a single dose (cycle 1 Day 1) and b multiple dose (cycle 1 Day 21) administration of oral suspension formulations. SD standard deviation
Fig. 3
Fig. 3
Kaplan-Meier plot of PFS (per RECIST v1.1) for patients with LGG (safety-evaluable patients). CI confidence interval, LGG low-grade glioma, NE not estimable, PFS progression-free survival, RECIST Response Evaluation Criteria in Solid Tumors
See this image and copyright information in PMC

References

    1. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291–3310. doi: 10.1038/sj.onc.1210422. - DOI - PubMed
    1. Forshew T, Tatevossian RG, Lawson AR, Ma J, Neale G, Ogunkolade BW, et al. Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol. 2009;218:172–181. doi: 10.1002/path.2558. - DOI - PubMed
    1. Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci USA. 2013;110:5957–5962. doi: 10.1073/pnas.1219232110. - DOI - PMC - PubMed
    1. Vitagliano O, Addeo R, D’Angelo V, Indolfi C, Indolfi P, Casale F. The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches. Expert Rev Hematol. 2013;6:587–597. doi: 10.1586/17474086.2013.827415. - DOI - PubMed
    1. Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014;4:216–231. doi: 10.1158/2159-8290.CD-13-0639. - DOI - PMC - PubMed

Publication types

Associated data